Study of Tislelizumab Plus Chemotherapy vs Chemotherapy as Perioperative Treatment in Participants With HER2 Negative Breast Cancer

Condition:   HER2-negative Breast Cancer Interventions:   Biological: Tislelizumab;   Drug: Nab paclitaxel;   Drug: Doxorubicin;   Drug: Epirubicin;   Device: Cyclophosphamide Sponsors:   Cancer Institute and Hospital, Chinese Academy of Medical Sciences;   First Affiliated Hospital Xi'an Jiaotong University;   Wuhan Union Hospital, China;   Beijing Huanxing Cancer Hospital Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials